½ÃÀ庸°í¼­
»óǰÄÚµå
1787011

¼¼°èÀÇ ¹æ»ç¼º ÀǾàǰ ½ÃÀå : ±Ô¸ð, Á¡À¯À², µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ - ¹æ»ç¼º µ¿À§ ¿ø¼Ò À¯Çüº°, ¿ëµµº°, °ø±Þ¿øº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ¿¹Ãø(2025-2034³â)

Radiopharmaceuticals Market Size, Share, Trends, & Industry Analysis Report By Radioisotope Type (Technetium-99, Fluorine-18), By Application, By Source, By End User, and By Region - Market Forecast, 2025-2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 129 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ¼¼°èÀÇ ¹æ»ç¼º ÀǾàǰ ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 209¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. ÀÌ Á¶»ç º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇÐÀ» ÀÚ¼¼È÷ ÆÄ¾ÇÇϰí ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

¹æ»ç¼º ÀǾàǰ ½ÃÀåÀº º´¿ø°ú ¿µ»ó Áø´Ü¼¾ÅͰ¡ Áø´Ü°ú Ä¡·áÀÇ ¾ç¸é¿¡¼­ ÇÙ ÀÇÇп¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³ôÀ̰í Àֱ⠶§¹®¿¡ ²ÙÁØÈ÷ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ Æ¯¼ö È­ÇÕ¹°Àº PET ¹× SPECT¿Í °°Àº °Ë»ç¿¡ »ç¿ëµÇ¸ç º´¸®ÇÐÀ» Á¶±â ¹× Á¤È®ÇÏ°Ô °¨ÁöÇÕ´Ï´Ù.

ÇöÀç ÁøÇà ÁßÀÎ ¿¬±¸°³¹ßÀº º¸´Ù Á¤È®ÇÏ°í ºÎÀÛ¿ëÀÌ ÀûÀº »õ·Î¿î ¹æ»ç¼º ÀǾàǰÀÇ °³¹ßÀ» ÁøÇàÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü´Â ÃֽŠ¿µ»ó Áø´Ü ½Ã½ºÅÛ¿¡ ÅõÀÚÇÏ¿© ÇÙÀÇÇÐ ºÎ¹®À» È®´ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ º¯È­´Â ȯÀÚÀÇ °á°ú¸¦ °³¼±ÇÏ°í °í±Þ Áø´Ü ¹× Ä¡·á ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù.

¹æ»ç¼º ÀǾàǰ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¹æ»ç¼º µ¿À§ ¿ø¼Ò À¯Çüº°·Î´Â »À, ½ÉÀå ¹× Á¾¾ç Áø´Ü°ú °ü·ÃµÈ Áúº´ÀÇ SPECT À̹Ì¡¿¡ ³Î¸® Àû¿ëµÇ´Â Å×Å©³×Ƭ-99 ºÎ¹®ÀÌ 2024³â ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.

¿ëµµº°·Î´Â ½Å°æ ºÐ¾ß°¡ 2024³â ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. ÀÌ´Â ¾Ï Áø´Ü, º´±â ºÐ·ù, Ä¡·á °èȹ¿¡ À־ ¹æ»ç¼º ÀǾàǰÀÇ Ã¤¿ëÀÌ È®´ëµÇ°í Àֱ⠶§¹®ÀÔ´Ï´Ù.

¼±¿øº°·Î´Â ¸ô¸®ºêµ§-99 µîÀÇ µ¿À§¿ø¼Ò°¡ ³Î¸® »ç¿ëµÇ°í Àֱ⠶§¹®¿¡ ¿øÀÚ·Î ºÐ¾ß°¡ 2024³â ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.

2024³â ¼¼°è ¹æ»ç¼º ÀǾàǰ ½ÃÀå¿¡¼­´Â ÇÙÀÇÇÐ ÀÎÇÁ¶ó Á¤ºñ°¡ ÁøÇàµÇ°í ÀÖ´Â ºÏ¹Ì°¡ ´ëºÎºÐÀÇ Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº Àεµ, Áß±¹, Çѱ¹ÀÇ °Ç°­ °ü¸® ÀÎÇÁ¶óÀÇ ±Þ¼ÓÇÑ ¼ºÀåÀ¸·Î »ó´çÇÑ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ÁÖ¿ä ½ÃÀå ±â¾÷Àº Advanced Accelerator Applications SA, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Bracco Imaging S.p.A., Cardinal Health, Inc., Curium Pharma, Eckert & Ziegler SE, F. Hoffmann-La Roche Ltd, GE HealthCare Technologies Inc., GlaxoSmithKline plc (GSK plc), Jubilant Radiopharma Limited, Lantheus Holdings, Inc., Eli Lilly and Company, Mallinckrodt plc µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ¹æ»ç¼º ÀǾàǰ ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ÇöȲ
  • ¹æ»ç¼ºÀǾàǰ ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
      • ¼¼°èÀûÀ¸·Î ¾Ï°ú ½ÉÇ÷°ü ÁúȯÀÌ Áõ°¡
      • ¼¼°è Àα¸ÀÇ °í·ÉÈ­
    • ¾ïÁ¦¿äÀΰú °úÁ¦
      • ³ôÀº »ý»ê ºñ¿ë°ú º¹ÀâÇÑ ±ÔÁ¦ ½ÂÀÎ
  • PESTEL ºÐ¼®
  • ¹æ»ç¼º ÀǾàǰ ½ÃÀå µ¿Çâ
  • ¹ë·ùüÀÎ ºÐ¼®

Á¦5Àå ¼¼°èÀÇ ¹æ»ç¼º ÀǾàǰ ½ÃÀå : ¹æ»ç¼º µ¿À§ ¿ø¼Ò À¯Çüº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
  • Å×Å©³×Ƭ 99
  • ºÒ¼Ò 18
  • ¿ä¿Àµå 131
  • ·çÅׯ¬ 177
  • ÀÌÆ®·ý 90
  • °¥·ý 68
  • °¥·ý 67
  • ·çºñµã 82
  • ¿ä¿Àµå 123
  • ¿ä¿Àµå 125
  • Àεã 111
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ ¹æ»ç¼º ÀǾàǰ ½ÃÀå : ¿ëµµº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
  • Á¾¾çÇÐ
  • ½ÉÀ庴ÇÐ
  • ¼ÒÈ­±â³»°ú
  • ½Å°æ³»ºÐºñÇÐ
  • ½Å°æÇÐ
  • ½ÅÀåÇÐ
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ ¹æ»ç¼º ÀǾàǰ ½ÃÀå : °ø±Þ¿øº° Àü¸Á

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
  • ¿øÀÚ·Î
  • »çÀÌŬ·ÎÆ®·Ð

Á¦8Àå ¼¼°èÀÇ ¹æ»ç¼º ÀǾàǰ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
  • º´¿ø
  • Áø´Ü¼¾ÅÍ
  • ¾Ï ¿¬±¸ ±â°ü
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ

Á¦9Àå ¼¼°èÀÇ ¹æ»ç¼º ÀǾàǰ ½ÃÀå : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼Ò°³
    • ¹æ»ç¼º ÀǾàǰ ½ÃÀå Æò°¡ : Áö¿ªº°, 2020-2034³â
  • ºÏ¹Ì
    • ºÏ¹Ì : ¹æ»ç¼º µ¿À§ ¿ø¼Ò À¯Çüº°, 2020-2034³â
    • ºÏ¹Ì : ¿ëµµº°, 2020-2034³â
    • ºÏ¹Ì : °ø±Þ¿øº° Àü¸Á, 2020-2034³â
    • ºÏ¹Ì : ÃÖÁ¾»ç¿ëÀÚº°, 2020-2034³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ : ¹æ»ç¼º µ¿À§ ¿ø¼Ò À¯Çüº°, 2020-2034³â
    • À¯·´ : ¿ëµµº°, 2020-2034³â
    • À¯·´ : °ø±Þ¿øº° Àü¸Á, 2020-2034³â
    • À¯·´ : ÃÖÁ¾»ç¿ëÀÚº°, 2020-2034³â
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³×´ú¶õµå
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¹æ»ç¼º µ¿À§ ¿ø¼Ò À¯Çüº°, 2020-2034³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ¿ëµµº°, 2020-2034³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : °ø±Þ¿øº° Àü¸Á, 2020-2034³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ÃÖÁ¾ »ç¿ëÀÚº°, 2020-2034³â
    • Áß±¹
    • Àεµ
    • ¸»·¹À̽þÆ
    • ÀϺ»
    • Àεµ³×½Ã¾Æ
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¹æ»ç¼º µ¿À§ ¿ø¼Ò À¯Çüº°, 2020-2034³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ¿ëµµº°, 2020-2034³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : °ø±Þ¿øº° Àü¸Á, 2020-2034³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ÃÖÁ¾»ç¿ëÀÚº°, 2020-2034³â
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¹æ»ç¼º µ¿À§ ¿ø¼Ò À¯Çüº°, 2020-2034³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ¿ëµµº°, 2020-2034³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : °ø±Þ¿øº° Àü¸Á, 2020-2034³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : ÃÖÁ¾»ç¿ëÀÚº°, 2020-2034³â
    • ¸ß½ÃÄÚ
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«

Á¦10Àå °æÀï ±¸µµ

  • È®´ë ¹× Àμö ºÐ¼®
    • È®´ë
    • Àμö
  • Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Advanced Accelerator Applications SA
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bracco Imaging SpA
  • Cardinal Health, Inc.
  • Curium Pharma
  • Eckert & Ziegler SE
  • F. Hoffmann-La Roche Ltd
  • GE HealthCare Technologies Inc.
  • GlaxoSmithKline plc(GSK plc)
  • Jubilant Radiopharma Limited
JHS 25.08.18

The radiopharmaceuticals market size is expected to reach USD 20.94 Billion by 2034, according to a new study by Polaris Market Research. The report "Radiopharmaceuticals Market Size, Share, Trends, & Industry Analysis Report By Radioisotope Type (Technetium-99, Fluorine-18), By Application, By Source, By End User, and By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The radiopharmaceuticals market is growing steadily as hospitals and imaging centers increasingly rely on nuclear medicine for both diagnosis and treatment. These specialized compounds are used in scans such as PET and SPECT to detect conditions early and accurately.

Ongoing research is leading to the development of new radiopharmaceuticals that are more precise and contains fewer side effects. Therefore, healthcare providers are investing in modern imaging systems and expanding nuclear medicine departments. This shift is improving patient outcomes, providing advanced diagnostic and therapeutic services.

Radiopharmaceuticals Market Report Highlights

Based on radioisotope type, the technetium-99 segment dominated the market in 2024, due to its widespread application in SPECT imaging for conditions related to bone, cardiac, and oncology diagnostics.

In terms of application, the neurology segment dominated the market in 2024. This is owing the growing adoption of radiopharmaceuticals in cancer diagnosis, staging, and treatment planning.

In terms of source, the nuclear reactors segment dominated the market in 2024, due to the extensive use of isotopes such as molybdenum-99.

North America accounted for the majority share in the global Radiopharmaceuticals market in 2024, due to advanced nuclear medicine infrastructure.

Asia Pacific held substantial market share, owing to rapid growth in healthcare infrastructure across India, China, and South Korea.

A few global key market players include Advanced Accelerator Applications SA, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Bracco Imaging S.p.A., Cardinal Health, Inc., Curium Pharma, Eckert & Ziegler SE, F. Hoffmann-La Roche Ltd, GE HealthCare Technologies Inc., GlaxoSmithKline plc (GSK plc), Jubilant Radiopharma Limited, Lantheus Holdings, Inc., Eli Lilly and Company, and Mallinckrodt plc.

Polaris Market Research has segmented the market report on the basis of type, application, source, end user, and region:

By Radioisotope Type Outlook (Revenue, USD Billion, 2020-2034)

Technetium-99

Fluorine-18

Iodine-131

Lutetium-177

Yttrium-90

Gallium-68

Gallium-67

Rubidium-82

Iodine-123

Iodine-125

Indium-111

Others

By Application Outlook (Revenue, USD Billion, 2020-2034)

Oncology

Cardiology

Gastroenterology

Neuroendocrinology

Neurology

Nephrology

Others

By Source Outlook (Revenue, USD Billion, 2020-2034)

Nuclear Reactors

Cyclotrons

By End User Outlook (Revenue, USD Billion, 2020-2034)

Hospitals

Diagnostic Centers

Cancer Research Institutes

Ambulatory Surgical Centers

Others

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Radiopharmaceuticals Market Insights

  • 4.1. Radiopharmaceuticals Market - Market Snapshot
  • 4.2. Radiopharmaceuticals Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Number of Cancer and Cardiovascular Diseases Globally
      • 4.2.1.2. Aging Global Population
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Production Costs and Complex Regulatory Approvals
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Radiopharmaceuticals Market Trends
  • 4.6. Value Chain Analysis

5. Global Radiopharmaceuticals Market, by Radioisotope Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
  • 5.3. Technetium-99
    • 5.3.1. Global Radiopharmaceuticals Market, by Technetium-99, by Region, 2020-2034 (USD Billion)
  • 5.4. Fluorine-18
    • 5.4.1. Global Radiopharmaceuticals Market, by Fluorine-18, by Region, 2020-2034 (USD Billion)
  • 5.5. Iodine-131
    • 5.5.1. Global Radiopharmaceuticals Market, by Iodine-131, by Region, 2020-2034 (USD Billion)
  • 5.6. Lutetium-177
    • 5.6.1. Global Radiopharmaceuticals Market, by Lutetium-177, by Region, 2020-2034 (USD Billion)
  • 5.7. Yttrium-90
    • 5.7.1. Global Radiopharmaceuticals Market, by Yttrium-90, by Region, 2020-2034 (USD Billion)
  • 5.8. Gallium-68
    • 5.8.1. Global Radiopharmaceuticals Market, by Gallium-68, by Region, 2020-2034 (USD Billion)
  • 5.9. Gallium-67
    • 5.9.1. Global Radiopharmaceuticals Market, by Gallium-67, by Region, 2020-2034 (USD Billion)
  • 5.10. Rubidium-82
    • 5.10.1. Global Radiopharmaceuticals Market, by Rubidium-82, by Region, 2020-2034 (USD Billion)
  • 5.11. Iodine-123
    • 5.11.1. Global Radiopharmaceuticals Market, by Iodine-123, by Region, 2020-2034 (USD Billion)
  • 5.12. Iodine-125
    • 5.12.1. Global Radiopharmaceuticals Market, by Iodine-125, by Region, 2020-2034 (USD Billion)
  • 5.13. Indium-111
    • 5.13.1. Global Radiopharmaceuticals Market, by Indium-111, by Region, 2020-2034 (USD Billion)
  • 5.14. Others
    • 5.14.1. Global Radiopharmaceuticals Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Radiopharmaceuticals Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
  • 6.3. Oncology
    • 6.3.1. Global Radiopharmaceuticals Market, by Oncology, by Region, 2020-2034 (USD Billion)
  • 6.4. Cardiology
    • 6.4.1. Global Radiopharmaceuticals Market, by Cardiology, by Region, 2020-2034 (USD Billion)
  • 6.5. Gastroenterology
    • 6.5.1. Global Radiopharmaceuticals Market, by Gastroenterology, by Region, 2020-2034 (USD Billion)
  • 6.6. Neuroendocrinology
    • 6.6.1. Global Radiopharmaceuticals Market, by Neuroendocrinology, by Region, 2020-2034 (USD Billion)
  • 6.7. Neurology
    • 6.7.1. Global Radiopharmaceuticals Market, by Neurology, by Region, 2020-2034 (USD Billion)
  • 6.8. Nephrology
    • 6.8.1. Global Radiopharmaceuticals Market, by Nephrology, by Region, 2020-2034 (USD Billion)
  • 6.9. Others
    • 6.9.1. Global Radiopharmaceuticals Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Radiopharmaceuticals Market, by Source Outlook

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
  • 7.3. Nuclear Reactors
    • 7.3.1. Global Radiopharmaceuticals Market, by Nuclear Reactors, by Region, 2020-2034 (USD Billion)
  • 7.4. Cyclotrons
    • 7.4.1. Global Radiopharmaceuticals Market, by Cyclotrons, by Region, 2020-2034 (USD Billion)

8. Global Radiopharmaceuticals Market, by End User

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 8.3. Hospitals
    • 8.3.1. Global Radiopharmaceuticals Market, by Hospitals, by Region, 2020-2034 (USD Billion)
  • 8.4. Diagnostic Centers
    • 8.4.1. Global Radiopharmaceuticals Market, by Diagnostic Centers, by Region, 2020-2034 (USD Billion)
  • 8.5. Cancer Research Institutes
    • 8.5.1. Global Radiopharmaceuticals Market, by Cancer Research Institutes, by Region, 2020-2034 (USD Billion)
  • 8.6. Ambulatory Surgical Centers
    • 8.6.1. Global Radiopharmaceuticals Market, by Ambulatory Surgical Centers, by Region, 2020-2034 (USD Billion)
  • 8.7. Others
    • 8.7.1. Global Radiopharmaceuticals Market, by Others, by Region, 2020-2034 (USD Billion)

9. Global Radiopharmaceuticals Market, by Geography

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Radiopharmaceuticals Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 9.3. Radiopharmaceuticals Market - North America
    • 9.3.1. North America: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.3.2. North America: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.3.3. North America: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.3.4. North America: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.3.5. Radiopharmaceuticals Market - U.S.
      • 9.3.5.1. U.S.: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.3.5.2. U.S.: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.3.5.3. U.S.: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.3.5.4. U.S.: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.3.6. Radiopharmaceuticals Market - Canada
      • 9.3.6.1. Canada: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.3.6.2. Canada: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.3.6.3. Canada: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.3.6.4. Canada: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.4. Radiopharmaceuticals Market - Europe
    • 9.4.1. Europe: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.4.2. Europe: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.4.3. Europe: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.4.4. Europe: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.4.5. Radiopharmaceuticals Market - UK
      • 9.4.5.1. UK: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.4.5.2. UK: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.4.5.3. UK: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.4.5.4. UK: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.4.6. Radiopharmaceuticals Market - France
      • 9.4.6.1. France: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.4.6.2. France: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.4.6.3. France: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.4.6.4. France: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.4.7. Radiopharmaceuticals Market - Germany
      • 9.4.7.1. Germany: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.4.7.2. Germany: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.4.7.3. Germany: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.4.7.4. Germany: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.4.8. Radiopharmaceuticals Market - Italy
      • 9.4.8.1. Italy: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.4.8.2. Italy: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.4.8.3. Italy: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.4.8.4. Italy: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.4.9. Radiopharmaceuticals Market - Spain
      • 9.4.9.1. Spain: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.4.9.2. Spain: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.4.9.3. Spain: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.4.9.4. Spain: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.4.10. Radiopharmaceuticals Market - Netherlands
      • 9.4.10.1. Netherlands: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.4.10.2. Netherlands: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.4.10.3. Netherlands: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.4.10.4. Netherlands: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.4.11. Radiopharmaceuticals Market - Russia
      • 9.4.11.1. Russia: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.4.11.2. Russia: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.4.11.3. Russia: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.4.11.4. Russia: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.4.12. Radiopharmaceuticals Market - Rest of Europe
      • 9.4.12.1. Rest of Europe: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.4.12.2. Rest of Europe: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.4.12.3. Rest of Europe: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.4.12.4. Rest of Europe: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.5. Radiopharmaceuticals Market - Asia Pacific
    • 9.5.1. Asia Pacific: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.5.2. Asia Pacific: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.5.3. Asia Pacific: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.5.4. Asia Pacific: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.5.5. Radiopharmaceuticals Market - China
      • 9.5.5.1. China: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.5.5.2. China: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.5.5.3. China: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.5.5.4. China: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.5.6. Radiopharmaceuticals Market - India
      • 9.5.6.1. India: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.5.6.2. India: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.5.6.3. India: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.5.6.4. India: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.5.7. Radiopharmaceuticals Market - Malaysia
      • 9.5.7.1. Malaysia: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.5.7.2. Malaysia: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.5.7.3. Malaysia: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.5.7.4. Malaysia: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.5.8. Radiopharmaceuticals Market - Japan
      • 9.5.8.1. Japan: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.5.8.2. Japan: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.5.8.3. Japan: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.5.8.4. Japan: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.5.9. Radiopharmaceuticals Market - Indonesia
      • 9.5.9.1. Indonesia: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.5.9.2. Indonesia: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.5.9.3. Indonesia: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.5.9.4. Indonesia: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.5.10. Radiopharmaceuticals Market - South Korea
      • 9.5.10.1. South Korea: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.5.10.2. South Korea: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.5.10.3. South Korea: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.5.10.4. South Korea: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.5.11. Radiopharmaceuticals Market - Australia
      • 9.5.11.1. Australia: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.5.11.2. Australia: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.5.11.3. Australia: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.5.11.4. Australia: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.5.12. Radiopharmaceuticals Market - Rest of Asia Pacific
      • 9.5.12.1. Rest of Asia Pacific: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.5.12.2. Rest of Asia Pacific: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.5.12.3. Rest of Asia Pacific: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.5.12.4. Rest of Asia Pacific: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.6. Radiopharmaceuticals Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.6.2. Middle East & Africa: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.6.3. Middle East & Africa: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.6.4. Middle East & Africa: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.6.5. Radiopharmaceuticals Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.6.6. Radiopharmaceuticals Market - UAE
      • 9.6.6.1. UAE: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.6.6.2. UAE: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.6.6.3. UAE: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.6.6.4. UAE: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.6.7. Radiopharmaceuticals Market - Israel
      • 9.6.7.1. Israel: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.6.7.2. Israel: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.6.7.3. Israel: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.6.7.4. Israel: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.6.8. Radiopharmaceuticals Market - South Africa
      • 9.6.8.1. South Africa: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.6.8.2. South Africa: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.6.8.3. South Africa: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.6.8.4. South Africa: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.6.9. Radiopharmaceuticals Market - Rest of Middle East & Africa
      • 9.6.9.1. Rest of Middle East & Africa: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.6.9.2. Rest of Middle East & Africa: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.6.9.3. Rest of Middle East & Africa: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.6.9.4. Rest of Middle East & Africa: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.7. Radiopharmaceuticals Market - Latin America
    • 9.7.1. Latin America: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.7.2. Latin America: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.7.3. Latin America: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.7.4. Latin America: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.7.5. Radiopharmaceuticals Market - Mexico
      • 9.7.5.1. Mexico: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.7.5.2. Mexico: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.7.5.3. Mexico: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.7.5.4. Mexico: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.7.6. Radiopharmaceuticals Market - Brazil
      • 9.7.6.1. Brazil: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.7.6.2. Brazil: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.7.6.3. Brazil: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.7.6.4. Brazil: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.7.7. Radiopharmaceuticals Market - Argentina
      • 9.7.7.1. Argentina: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.7.7.2. Argentina: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.7.7.3. Argentina: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.7.7.4. Argentina: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
    • 9.7.8. Radiopharmaceuticals Market - Rest of Latin America
      • 9.7.8.1. Rest of Latin America: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
      • 9.7.8.2. Rest of Latin America: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
      • 9.7.8.3. Rest of Latin America: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
      • 9.7.8.4. Rest of Latin America: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Advanced Accelerator Applications SA
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. AstraZeneca plc
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Bayer AG
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Boehringer Ingelheim International GmbH
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Bracco Imaging S.p.A.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Cardinal Health, Inc.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Curium Pharma
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Eckert & Ziegler SE
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. F. Hoffmann-La Roche Ltd
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. GE HealthCare Technologies Inc.
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. GlaxoSmithKline plc (GSK plc)
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Jubilant Radiopharma Limited
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦